Affibody® molecules: New protein domains for molecular imaging and targeted tumor therapy

Fredrik Y. Nilsson, Vladimir Tolmachev

Research output: Contribution to journalReview articlepeer-review

109 Citations (Scopus)

Abstract

Molecular imaging shows promise as a useful tool to aid drug discovery and development and also to provide important prognostic and predictive diagnostic information affecting patient management in the clinic. However, the use of molecular imaging diagnostically is not widely adopted, in part due to the lack of suitable targeting agents. Affibody molecules are a class of small and very stable protein domains, which can be used to selectively address a wide range of protein targets. Their small size enables high contrast radionuclide imaging and they can be produced by conventional peptide synthesis methods. Their potential utility in molecular imaging is highlighted in a large number of animal studies using anti-HER2 Affibody tracers and has recently been validated in breast cancer patients with HER2-expressing metastases. The therapeutic efficacy of the Affibody molecules in this indication was demonstrated in preclinical models using a targeted radionuclide as the effector function. This review will focus on the recent use of Affibody molecules for molecular imaging and their application for radioimmunotherapy.

Original languageEnglish
Pages (from-to)167-175
Number of pages9
JournalCurrent Opinion in Drug Discovery and Development
Volume10
Issue number2
Publication statusPublished - Mar 2007
Externally publishedYes

Keywords

  • Affibody molecules
  • HER2
  • Molecular imaging
  • Radioimmunotherapy
  • Radionuclide diagnostics
  • Tumor targeting
  • Tumor therapy
  • Xenograft

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Affibody® molecules: New protein domains for molecular imaging and targeted tumor therapy'. Together they form a unique fingerprint.

Cite this